Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on November 3, 2020, covering events occurring on October 30, 2020. The filing primarily addresses the appointment of a new executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The material change reported is the appointment of Randy J. Maddux as Chief Operating Officer (COO), effective December 1, 2020. Mr. Maddux joins from Aptevo Therapeutics Inc., where he served as Senior Vice President of Operations and Chief Manufacturing Officer.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the new COO, which include:
- Base Salary: $390,000 annually, accruing from the effective date.
- Signing Bonus: $160,000, payable within 30 days of the effective date, subject to a clawback provision if he resigns without good reason within 12 months.
- Annual Bonus: Target of 40% of base salary, based on performance.
- Equity Grants:
- 465,000 stock options vesting ratably (25% after one year, then 6.25% every three months).
- 309,000 Restricted Stock Units (RSUs) vesting in even increments over three years.
- Severance:
- Termination without Cause: 9 months of base salary, target bonus, and 9 months of health benefits.
- Termination without Cause within 12 months of a Change of Control (or Good Reason resignation): 12 months of base salary, target bonus, immediate 100% vesting of unvested equity, and 12 months of health benefits.
The filing contains no specific guidance on future financial performance or operational outlook beyond the leadership change.
Investor Verification Checklist
- Verify the effective date of the COO appointment (December 1, 2020) and completion of pre-employment procedures.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the impact of the $160,000 signing bonus and equity grants on the company's cash flow and dilution.
- Check subsequent filings for updates on the company's operational strategy under the new leadership.